Vericiguat: A New Hope for Heart Failure Patients
Heart failure with reduced ejection fraction (HFrEF) is the inability of the heart to adequately contract or eject blood. This heart is unable to produce adequate cardiac output to perfuse vital tissues. At a fundamental level, it is known that the cardioprotective pathway of nitric oxide-soluble gu...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Cardiovascular Therapeutics |
| Online Access: | http://dx.doi.org/10.1155/2022/1554875 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568163011657728 |
|---|---|
| author | Raquel Chiles Rami A. Al-Horani |
| author_facet | Raquel Chiles Rami A. Al-Horani |
| author_sort | Raquel Chiles |
| collection | DOAJ |
| description | Heart failure with reduced ejection fraction (HFrEF) is the inability of the heart to adequately contract or eject blood. This heart is unable to produce adequate cardiac output to perfuse vital tissues. At a fundamental level, it is known that the cardioprotective pathway of nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate is impaired in heart failure patients. Vericiguat is a novel, orally used, small molecule, and direct stimulator of the soluble guanylate cyclase, and thus, it enhances the production of cyclic guanosine monophosphate. Vericiguat was approved by the FDA in January of 2021 to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic heart failure and ejection fraction less than 45%. In this review, we describe the chemical and mechanistic aspects, pharmacokinetics, adverse effects, and contraindications of vericiguat so as to facilitate its optimal therapeutic use. |
| format | Article |
| id | doaj-art-a88cd3a5cac244d79aeebe90245d8f60 |
| institution | Kabale University |
| issn | 1755-5922 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiovascular Therapeutics |
| spelling | doaj-art-a88cd3a5cac244d79aeebe90245d8f602025-02-03T00:59:38ZengWileyCardiovascular Therapeutics1755-59222022-01-01202210.1155/2022/1554875Vericiguat: A New Hope for Heart Failure PatientsRaquel Chiles0Rami A. Al-Horani1Division of Basic Pharmaceutical SciencesDivision of Basic Pharmaceutical SciencesHeart failure with reduced ejection fraction (HFrEF) is the inability of the heart to adequately contract or eject blood. This heart is unable to produce adequate cardiac output to perfuse vital tissues. At a fundamental level, it is known that the cardioprotective pathway of nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate is impaired in heart failure patients. Vericiguat is a novel, orally used, small molecule, and direct stimulator of the soluble guanylate cyclase, and thus, it enhances the production of cyclic guanosine monophosphate. Vericiguat was approved by the FDA in January of 2021 to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic heart failure and ejection fraction less than 45%. In this review, we describe the chemical and mechanistic aspects, pharmacokinetics, adverse effects, and contraindications of vericiguat so as to facilitate its optimal therapeutic use.http://dx.doi.org/10.1155/2022/1554875 |
| spellingShingle | Raquel Chiles Rami A. Al-Horani Vericiguat: A New Hope for Heart Failure Patients Cardiovascular Therapeutics |
| title | Vericiguat: A New Hope for Heart Failure Patients |
| title_full | Vericiguat: A New Hope for Heart Failure Patients |
| title_fullStr | Vericiguat: A New Hope for Heart Failure Patients |
| title_full_unstemmed | Vericiguat: A New Hope for Heart Failure Patients |
| title_short | Vericiguat: A New Hope for Heart Failure Patients |
| title_sort | vericiguat a new hope for heart failure patients |
| url | http://dx.doi.org/10.1155/2022/1554875 |
| work_keys_str_mv | AT raquelchiles vericiguatanewhopeforheartfailurepatients AT ramiaalhorani vericiguatanewhopeforheartfailurepatients |